A Study to Evaluate the Efficacy and Safety of VCT220 in Obesity Chinese Population

Summary

The goal of the study is to assess how VCT220 tablets affect the bodyweight when used once daily in obese or overweight adult participants Qualified participants will be randomly assigned to one of four groups using a computerized system. Participants will get VCT220 or placebo tablets for 16 weeks and will need to take tablets each morning. Participants will have 7 clinic visits and a final follow-up visit approximately 14 days after the last study intervention administration.

Timeline

Start

2023-12-27

Primary completion

2024-07-13

Completion

2024-08-01

Drugs

Indications